DETECTR can be adapted to detect various cancer-related mutations, such as those in oncogenes (e.g., KRAS, BRAF) or tumor suppressor genes (e.g., TP53), after detecting circulating tumor DNA (ctDNA) in blood samples. This evidence concerns the gene TP53 and neoplasm.